Results 1 to 10 of about 9,532 (200)
Seizures Associated With Bone Density Conservation Agents [PDF]
Journal of Pharmacy Technology, 2022 Objective The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA). Data Sources A comprehensive literature review was performed between September and October 2021 using the following keywords: osteoporosis/drug therapy, seizures ...
Kuan Sturgill, Justin P. Reinert
europepmc +5 more sources
Therapeutic Drug Review on Romosozumab: The First Sclerostin Inhibitor [PDF]
Journal of Clinical and Diagnostic Research, 2022 Osteoporosis is a progressive skeletal disorder which is characterised by low bone mass, normal mineralisation and abnormal bone microarchitecture. This disruption of bone microarchitecture causes subsequent increase in bone fragility and raises risk of ...
Vijay Kumar Jain +3 more
doaj +1 more source
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis
Frontiers in Endocrinology, 2021 Glucocorticoid-induced osteoporosis (GIOP) leads to fractures in up to 40% of patients with chronic glucocorticoid (GC) therapy when left untreated. GCs rapidly increase fracture risk, and thus many patients with anticipated chronic GC exposures should ...
Kaleen N. Hayes +5 more
doaj +1 more source
Transplantation Reports, 2022 Background: Osteoporosis is a prevalent complication in heart transplant population. Denosumab is a monoclonal antibody that inhibits bone resorption approved for the treatment of corticosteroid-induced osteoporosis and potentially useful in heart ...
Juan C. Uzquiano +5 more
doaj +1 more source
Journal of Bone Oncology, 2022 Background: Giant-cell tumor of bone (GCTB) is a relatively benign, but locally aggressive osteoclastogenic stromal tumour of the bone. Although denosumab has been approved as an monoclonal antibody against RANK ligand for the treatment of GCTB, few ...
Jiaji Yue, Wei Sun, Shenglong Li
doaj +1 more source
Dental Evaluation Prior to Cancer Therapy
Frontiers in Oral Health, 2022 A comprehensive oral examination and dental care prior to the start of cancer therapy is the standard of care in many cancer centers. This is because good oral health will likely minimize the undesirable complications such as opportunistic infections ...
Chee Weng Yong +2 more
doaj +1 more source
Acta Stomatologica Croatica, 2023 Antiresorptive drugs (AR) have been used for many years in the treatment of various bone conditions such as osteoporosis, osteopenia, Paget’s disease, bone metastases, multiple myeloma and the associated malignant hypercalcemia.
Sven Bival +5 more
doaj +1 more source
Pesquisa Brasileira em Odontopediatria e Clínica Integrada, 2023 Objective: To determine the level of scientific information of dental surgeons who carry out their professional activities in Brazil about antiresorptive drugs and indicated pharmacological procedures aiming at the prevention of osteonecrosis of the jaws
Flávia Godinho Costa Wanderley Rocha +1 more
doaj
Journal of Bone Oncology, 2019 Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj +1 more source
Bone Reports, 2019 Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing ...
Chad L. Deal +4 more
doaj +1 more source